Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 24323 | 7.68 |
09:34 ET | 15328 | 7.72 |
09:36 ET | 2509 | 7.73 |
09:38 ET | 3300 | 7.735 |
09:39 ET | 61507 | 7.69 |
09:41 ET | 1320 | 7.7002 |
09:43 ET | 1300 | 7.68 |
09:45 ET | 2414 | 7.71 |
09:48 ET | 1700 | 7.71 |
09:50 ET | 2029 | 7.6996 |
09:52 ET | 13572 | 7.68 |
09:54 ET | 7061 | 7.69 |
09:56 ET | 4135 | 7.73 |
09:57 ET | 969 | 7.715 |
09:59 ET | 1200 | 7.67 |
10:01 ET | 5690 | 7.695 |
10:03 ET | 700 | 7.72 |
10:06 ET | 9493 | 7.77 |
10:08 ET | 1600 | 7.8 |
10:10 ET | 3043 | 7.75 |
10:12 ET | 9049 | 7.73 |
10:14 ET | 1428 | 7.72 |
10:15 ET | 7400 | 7.71 |
10:17 ET | 618 | 7.72 |
10:19 ET | 3200 | 7.71 |
10:21 ET | 2930 | 7.69 |
10:24 ET | 3540 | 7.71 |
10:26 ET | 724 | 7.75 |
10:28 ET | 1445 | 7.76 |
10:30 ET | 22504 | 7.8 |
10:32 ET | 5109 | 7.78 |
10:33 ET | 499 | 7.8 |
10:35 ET | 15022 | 7.8215 |
10:37 ET | 2272 | 7.86 |
10:39 ET | 18038 | 7.8305 |
10:42 ET | 5922 | 7.84 |
10:44 ET | 3357 | 7.821 |
10:46 ET | 9844 | 7.85 |
10:48 ET | 6169 | 7.88 |
10:50 ET | 4251 | 7.89 |
10:51 ET | 5451 | 7.89 |
10:53 ET | 52437 | 7.84 |
10:55 ET | 3832 | 7.85 |
10:57 ET | 13547 | 7.8 |
11:00 ET | 1164 | 7.83 |
11:02 ET | 4671 | 7.81 |
11:04 ET | 7455 | 7.76 |
11:06 ET | 600 | 7.77 |
11:08 ET | 6251 | 7.75 |
11:09 ET | 1762 | 7.73 |
11:11 ET | 500 | 7.71 |
11:13 ET | 2677 | 7.71 |
11:15 ET | 700 | 7.71 |
11:18 ET | 2600 | 7.74 |
11:20 ET | 1842 | 7.72 |
11:22 ET | 28614 | 7.68 |
11:24 ET | 5214 | 7.7099 |
11:26 ET | 11367 | 7.69 |
11:27 ET | 300 | 7.7 |
11:29 ET | 18208 | 7.69 |
11:31 ET | 2220 | 7.72 |
11:33 ET | 1909 | 7.72 |
11:36 ET | 900 | 7.72 |
11:38 ET | 1518 | 7.73 |
11:40 ET | 1019 | 7.73 |
11:42 ET | 2199 | 7.74 |
11:44 ET | 400 | 7.73 |
11:45 ET | 871 | 7.74 |
11:47 ET | 509 | 7.75 |
11:49 ET | 821 | 7.73 |
11:51 ET | 1129 | 7.73 |
11:54 ET | 680 | 7.73 |
11:56 ET | 2440 | 7.7202 |
11:58 ET | 1000 | 7.72 |
12:00 ET | 7368 | 7.7002 |
12:02 ET | 7668 | 7.725 |
12:03 ET | 900 | 7.72 |
12:05 ET | 400 | 7.74 |
12:07 ET | 600 | 7.74 |
12:09 ET | 5700 | 7.76 |
12:12 ET | 3056 | 7.77 |
12:14 ET | 5400 | 7.75 |
12:16 ET | 100 | 7.73 |
12:18 ET | 400 | 7.74 |
12:20 ET | 3508 | 7.76 |
12:21 ET | 1521 | 7.79 |
12:23 ET | 700 | 7.79 |
12:25 ET | 300 | 7.8 |
12:27 ET | 2900 | 7.81 |
12:30 ET | 3970 | 7.802 |
12:32 ET | 5793 | 7.78 |
12:34 ET | 5014 | 7.77 |
12:36 ET | 500 | 7.79 |
12:38 ET | 1082 | 7.78 |
12:39 ET | 790 | 7.79 |
12:41 ET | 4600 | 7.8064 |
12:43 ET | 10746 | 7.81 |
12:45 ET | 5289 | 7.79 |
12:48 ET | 3190 | 7.77 |
12:50 ET | 600 | 7.76 |
12:52 ET | 1709 | 7.8 |
12:54 ET | 1434 | 7.79 |
12:56 ET | 3600 | 7.79 |
12:57 ET | 4140 | 7.76 |
12:59 ET | 2944 | 7.759 |
01:01 ET | 3313 | 7.8 |
01:03 ET | 2531 | 7.78 |
01:06 ET | 7122 | 7.8199 |
01:08 ET | 2000 | 7.8 |
01:10 ET | 3240 | 7.77 |
01:12 ET | 3500 | 7.74 |
01:14 ET | 5123 | 7.71 |
01:15 ET | 5191 | 7.72 |
01:17 ET | 4750 | 7.7002 |
01:19 ET | 2450 | 7.71 |
01:21 ET | 4118 | 7.75 |
01:24 ET | 800 | 7.75 |
01:26 ET | 500 | 7.74 |
01:28 ET | 781 | 7.73 |
01:30 ET | 6993 | 7.74 |
01:32 ET | 4467 | 7.73 |
01:33 ET | 2826 | 7.73 |
01:35 ET | 2745 | 7.75 |
01:37 ET | 400 | 7.76 |
01:39 ET | 1610 | 7.75 |
01:42 ET | 2532 | 7.74 |
01:44 ET | 3458 | 7.76 |
01:46 ET | 900 | 7.76 |
01:48 ET | 800 | 7.75 |
01:50 ET | 4550 | 7.78 |
01:51 ET | 3121 | 7.76 |
01:53 ET | 508 | 7.76 |
01:55 ET | 858 | 7.79 |
01:57 ET | 2200 | 7.79 |
02:00 ET | 1008 | 7.79 |
02:02 ET | 3263 | 7.76 |
02:04 ET | 3349 | 7.74 |
02:06 ET | 3000 | 7.742 |
02:08 ET | 6035 | 7.77 |
02:09 ET | 4051 | 7.77 |
02:11 ET | 3974 | 7.73 |
02:13 ET | 779 | 7.73 |
02:15 ET | 1302 | 7.73 |
02:18 ET | 600 | 7.73 |
02:20 ET | 1076 | 7.74 |
02:22 ET | 1957 | 7.75 |
02:24 ET | 867 | 7.75 |
02:26 ET | 1800 | 7.72 |
02:27 ET | 2517 | 7.741 |
02:29 ET | 2515 | 7.74 |
02:31 ET | 2878 | 7.75 |
02:33 ET | 2396 | 7.76 |
02:36 ET | 75841 | 7.81 |
02:38 ET | 1829 | 7.81 |
02:40 ET | 2011 | 7.82 |
02:42 ET | 25510 | 7.84 |
02:44 ET | 6716 | 7.85 |
02:45 ET | 25163 | 7.84 |
02:47 ET | 2558 | 7.84 |
02:49 ET | 6830 | 7.8529 |
02:51 ET | 7364 | 7.85 |
02:54 ET | 1928 | 7.85 |
02:56 ET | 5244 | 7.87 |
02:58 ET | 6629 | 7.84 |
03:00 ET | 2214 | 7.85 |
03:02 ET | 500 | 7.85 |
03:03 ET | 1900 | 7.86 |
03:05 ET | 1640 | 7.83 |
03:07 ET | 2161 | 7.84 |
03:09 ET | 3979 | 7.87 |
03:12 ET | 3068 | 7.86 |
03:14 ET | 3293 | 7.86 |
03:16 ET | 1000 | 7.87 |
03:18 ET | 3700 | 7.86 |
03:20 ET | 1675 | 7.85 |
03:21 ET | 984 | 7.87 |
03:23 ET | 9650 | 7.86 |
03:25 ET | 5082 | 7.88 |
03:27 ET | 13357 | 7.89 |
03:30 ET | 6250 | 7.865 |
03:32 ET | 1246 | 7.87 |
03:34 ET | 1624 | 7.88 |
03:36 ET | 8352 | 7.9 |
03:38 ET | 8323 | 7.93 |
03:39 ET | 32608 | 7.9 |
03:41 ET | 10490 | 7.8701 |
03:43 ET | 8861 | 7.85 |
03:45 ET | 9632 | 7.83 |
03:48 ET | 10839 | 7.825 |
03:50 ET | 10828 | 7.825 |
03:52 ET | 14049 | 7.83 |
03:54 ET | 21068 | 7.845 |
03:56 ET | 21183 | 7.845 |
03:57 ET | 36037 | 7.88 |
03:59 ET | 38108 | 7.87 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.5B | -47.5x | --- |
Viking Therapeutics Inc | 5.2B | -54.6x | --- |
Nuvalent Inc | 5.2B | -31.9x | --- |
Immunitybio Inc | 5.0B | -6.2x | --- |
Madrigal Pharmaceuticals Inc | 6.0B | -12.4x | --- |
Krystal Biotech Inc | 5.2B | 97.2x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -47.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.